



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Early experience in Paris with the impact of the COVID-19 pandemic on vascular surgery



April 6, 2020, day 20 since the general lockdown in France. The Paris area is the heart of the COVID-19 pandemic in our country. Five years after the Paris terrorist attack in 2015, the Parisian health care system is again facing an unprecedented challenge. But this time we are urgently in need of intensive care unit (ICU) beds, ventilators, and personal protective equipment rather than operating rooms (ORs). Our ICU capacities have been doubled by transforming any available space with ventilators into ICUs: recovery rooms, outpatient surgical units, even ORs. To spare most of the in-hospital resources, all nonemergent surgical procedures have been canceled. ORs are used to manage emergencies only. According to the French Society for Vascular Surgery's recommendations based on the 3Ss principle (save Staff, Space, and Stuff), our surgical activity is now limited to the following emergencies: acute aortic syndromes, critical and acute limb ischemia, symptomatic carotid stenosis, mesenteric ischemia, and vascular access for hemodialysis, with endovascular favored over open repair whenever possible to shorten hospital and ICU stay.

By the end of March, ICU capacities quickly became saturated in most of our centers, which made acute vascular patient referrals very difficult. To coordinate and optimize acute patient referrals, we created secured social network groups including all vascular surgery consultants from both public and private hospitals in the Paris area. These groups allowed us to share clinical experience and to set up clinical studies. ICUs have been divided into COVID-19-positive and COVID-19-negative units. Therefore, systematic preoperative screening for COVID-19 should be recommended. Suspected cases might be considered positive. No COVID-19-negative center could have been preserved because of the magnitude of the pandemic.

Most important, we have observed a rising number of acute arterial events in COVID-19 patients with no prior vascular history, as related by Zhang et al.¹ These vascular complications include acute thrombosis of the abdominal aorta and carotid and peripheral arteries and can be the revealing symptom of COVID-19. The assumption of a COVID-19-related hypercoagulability is supported by high reported rates of deep venous and pulmonary thromboembolism and the identification of a disseminated intravascular coagulation in COVID-19 ICU patients.² Our group is conducting a clinical study of vascular events in COVID-19 patients.

Regarding staff management, our daily rotations have been completely modified, with one team dedicated to vascular emergencies in each center. The remaining team members participate in COVID-19-related activities in acute COVID-19 units and ensure telemedicine

outpatient follow-up. In the ICU, we flip ventilated patients into the prone position and perform central line placement. For vascular outpatient clinics, phone interviews have replaced classic clinics.

Surprisingly, we have observed a significant decrease in overall vascular referrals, as has been observed for stroke and myocardial infarction. This might be a collateral damage of the pandemic that dissuades our fragile patients from consulting emergency departments. We will probably face a postpandemic wave of patients with severe vascular conditions.

To conclude, we would like to warn the vascular community about acute arterial thromboembolic events that might be related to COVID-19 disease.

Iannis Ben Abdallah, MD, on behalf of La Collégiale APHP

Paris Association of Vascular Surgeons
Assistance Publique-Hôpitaux de Paris
Paris, France

REFERENCES

1. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med* 2020;382:e38.
2. J. Wang, N. Hajizadeh, E.E. Moore, R.C. McIntyre, P.K. Moore, L.A. Veress, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series [published online ahead of print April 8, 2020]. *J Thromb Haemost* doi: 10.1111/jth.14828.

<https://doi.org/10.1016/j.jvs.2020.04.467>

Doing the right thing for the right reason when treating ruptured abdominal aortic aneurysms in the COVID-19 era



The recent COVID-19 pandemic has increased the workload of health services worldwide, especially in regard to availability of intensive care unit (ICU) beds. The need of spare ICU beds in favor of COVID-19 patients increases the danger of diminished treatment options for patients suffering from other diseases, especially where resources are limited.

Patients with ruptured abdominal aortic aneurysms (rAAAs) are among those who may need the ICU postoperatively. Open repair increases both the intraoperative complexity of treatment and the need for postoperative intensive care. On the other hand, endovascular aneurysm repair (EVAR) can be performed under local anesthesia, and a successful outcome is usually accompanied by short recovery and quick turnover.

We recently admitted a 78-year-old man with a rAAA. He presented with lumbar pain and hypotension. Because of the COVID-19 pandemic, there was no bed available in the ICU. The patient underwent an emergency endovascular repair under local anesthesia using

an Ankura endograft (Lifetech, Shenzhen, China). He received only 3 packs of red blood cells intraoperatively, and after the procedure, he was transferred immediately to the vascular surgery ward. No ICU was needed. He had an uneventful recovery, with full mobilization and oral feeding from the first postoperative day and discharge on the second postoperative day.

Although the type of treatment of rAAA is still debatable,¹ EVAR is considered the first treatment option in an increasing number of vascular departments worldwide because of the reduced perioperative risk and shorter postoperative in-hospital length of stay.² Definitely, the low number suitable for endovascular repair³ should be taken into consideration. The 2018 guidelines for the treatment of AAA recommend EVAR over open repair in anatomically suitable patients with rAAA.² Performing the procedure under local anesthesia is an additional advantage. In a recent analysis of the Vascular Quality Initiative database, patients with rAAA who were treated with EVAR under local anesthesia compared with EVAR under general anesthesia had decreased intraoperative time, decreased number of intraoperative blood transfusions, decreased ICU length of stay, and fewer postoperative pulmonary complications.⁴

Today, when everyone in the health care system struggles with challenges posed by the coronavirus, every choice should be made with the concept in mind of “doing the right thing for the right reason.” Using EVAR, if it is anatomically possible, under local anesthesia rather than open repair or EVAR under general anesthesia seems to be the best solution. This way, we can achieve both goals at the same time, that is, treating patients in danger and saving valuable health care resources.

Christos Verikokos, MD

Andreas M. Lazaris, MD, FACS, FEBVS

George Geroulakos, MD, PhD, FRCS

Vascular Surgery Department
Attikon University Hospital
National and Kapodistrian University of Athens
Athens, Greece

C.V. and A.L. share co-first authorship.

REFERENCES

1. IMPROVE Trial Investigators, Powell JT, Sweeting MJ, Thompson MM, Ashleigh R, Bell R, Gomes M, et al. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomized trial. *BMJ* 2014;348:f7661.
2. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg* 2018;67:2-77.e2.
3. Hoornweg LL, Wisselink W, Vahl A, Balm R; Amsterdam Acute Aneurysm Trial Collaborators. The Amsterdam Acute Aneurysm Trial: suitability and application rate for endovascular

repair of ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 2007;33:679-83.

4. Faizer R, Weinhandl E, El Hag, Le Jeune S, Apostolidou I, Shafii SM, et al. Decreased mortality with local versus general anesthesia in endovascular aneurysm repair for ruptured abdominal aortic aneurysm in the Vascular Quality Initiative database. *J Vasc Surg* 2019;70:92-101.

<https://doi.org/10.1016/j.jvs.2020.04.009>

Time to pause, to think, and to recalibrate after COVID-19



It is an eerie feeling entering the theater complex. All elective surgery has stopped as theaters have been converted to additional intensive treatment unit pods, with emergency work restricted to one designated theater.

The number of emergencies has fallen as people stay away from hospitals and surgeons follow the COVID-19 guidelines to reduce the risk of infection to staff and patients.¹ The recommendation is to avoid surgery where possible, especially if it avoids admission and use of an intensive treatment unit bed.^{2,3} There are, however, differences across the United Kingdom and the United States regarding the specifics in the advice.^{4,5} Some of the recommendations are based not on data but on exercising the most cautious and protective approach possible.⁶ Surgeons' and theater staff's risk of acquiring an infection is higher because of a combination of factors and the ability of the virus to remain viable on surfaces for a long time.^{7,8}

It will be interesting to see what happens when we get back to normality again and start seeing patients face to face, instead of virtual consultations on the phone. What will that normality look like for each specialty and for patients who did not get their urgent surgery? It will be interesting to note how many diabetic feet get septic without their urgent débridement or end up with major amputations without their urgent angioplasties and bypasses.

For stroke and transient ischemic attack patients with significant carotid artery stenosis who do not undergo carotid endarterectomy within 7 days, the COVID-19 era will be a defining moment for those championing the benefit of the modern best medical management. It will be a chance to see how many such patients end up with a major stroke within the next 3 months and if the carotid stenting rate goes up.

Similarly, for renal access, no new arteriovenous fistulas or grafts are being made. We are just dealing with complications like infections and blowouts of the old ones. All new starters, crash landers, and those with problematic arteriovenous fistulas are having tunneled lines inserted, with possibly a greater rate of infections as time may tell?